Retinal changes after fluocinolone acetonide implant (ILUVIEN®) for DME: SD-OCT imaging assessment using ESASO...

Area of Science:

• Ophthalmology
• Retinal Diseases
• Pharmacological Treatments

Background:

• Diabetic macular edema (DME) presents persistent or recurrent challenges in management.
• Understanding retinal structural changes post-treatment is crucial for improving outcomes.

Purpose of the Study:

• To assess the anatomical and structural retinal changes following intravitreal fluocinolone acetonide implantation in persistent or recurrent DME.
• To evaluate the long-term efficacy of the implant in managing DME.

Main Methods:

• 45 eyes with refractory center-involved DME received intravitreal fluocinolone acetonide implants.
• Patients were monitored for best-corrected visual acuity (BCVA), central foveal thickness (CFT), and key retinal parameters over 36 months.

Main Results:

• Significant improvements in BCVA, CFT, and maculopathy stage were observed within 6 months and maintained at 36 months.
• Reduced intraretinal cysts and improved retinal integrity (ellipsoid zone, external limiting membrane) were noted.
• Early treatment trended towards better outcomes, though not statistically significant.

Conclusions:

• Intravitreal fluocinolone acetonide implantation is effective for persistent or recurrent DME.
• The implant improves maculopathy stage, reduces intraretinal cysts, and enhances BCVA and CFT.
• Sustained anatomical and visual improvements support its role in DME management.